Deposition of mutant ubiquitin in parkinsonism–dementia complex of Guam
© The Author(s). 2017
Received: 12 October 2017
Accepted: 2 November 2017
Published: 9 November 2017
Guam parkinsonism–dementia complex (G-PDC) is an enigmatic neurodegenerative disease that affects the Chamorro residents of the Pacific island of Guam. G-PDC is clinically characterized by progressive cognitive impairment with extrapyramidal signs. Pronounced loss of neurons and abundant neurofibrillary tangles (NFTs) are observed throughout the brain of G-PDC patients [6, 7]. Although several hypotheses have been suggested for the cause of G-PDC, notably genetic predisposition and exposure to neurotoxins (e.g., β-N-methylamino-L-alanine (BMAA)), the etiology and pathogenesis remain elusive .
Description of the subjects
Age of death (years)
Age of onset (years)
Disease duration (months)
Brain weight (g)
Cause of death
perforated gastric ulcer
< 10 h
This demonstration of UBB+1-immunoreactivity and accumulation of particular UPS components in G-PDC brains (n = 6) might have important implications for understanding of the pathological mechanisms underlying the disease. UBB+1 has previously been shown to induce neuronal defects in in vitro and in vivo experimental models: long-term UPS inhibition due to UBB+1 expression causes memory deficits and central breathing dysfunction in mice [4, 8, 11]. In addition, UBB+1 might act as a modifier of other pathology in G-PDC. For example, UBB+1 may enhance the aggregation and cellular toxicity of the RNA-binding protein TDP-43 through interfering with its degradation. It is striking that UBB+1 accumulates in glial cells in G-PDC, because similar glial inclusions have been reported in progressive supranuclear palsy (PSP) , a disease that displays some similar topography of neurofibrillary degeneration . Recognition of common mechanistic themes shared by neurodegenerative disorders, such as dysfunctional (ubiquitin-dependent) protein degradation and proteotoxic stress, may help in identifying therapeutic targets that prevent neurodegeneration. It will be interesting to investigate the potential contribution of disrupted proteostasis and UBB+1 to G-PDC in more detail in future studies.
We thank Drs. J.-M. Graïc, J.J. van Heerikhuize and D.F. Swaab (Netherlands Institute for Neuroscience (NIN), Amsterdam, The Netherlands) for assistance and Dr. R.A.I. de Vos (Laboratory of Pathology, Enschede, The Netherlands) for advice.
Ethics approval and consent to participate
This study was conducted with the approval of the Ethical Committee of Shinshu University School of Medicine (No. 1565).
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- de Pril R, Fischer DF, Maat-Schieman MLC, Hobo B, De Vos RAI, Brunt ER, Hol EM, Roos RAC, Van Leeuwen FW (2004) Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum Mol Genet 13:1803–1813. doi:10.1093/hmg/ddh188 View ArticlePubMedGoogle Scholar
- Dennissen FJA, Kholod N, Hermes DJHP, Kemmerling N, Steinbusch HWM, Dantuma NP, Van Leeuwen FW (2011) Mutant ubiquitin (UBB+1) associated with neurodegenerative disorders is hydrolyzed by ubiquitin C-terminal hydrolase L3 (UCH-L3). FEBS Lett 585:2568–2574. doi:10.1016/j.febslet.2011.06.037 View ArticlePubMedGoogle Scholar
- Fischer DF, De Vos RAI, Van Dijk R, De Vrij FMS, Proper EA, Sonnemans MAF, Verhage MC, Sluijs JA, Hobo B, Zouambia M, Steur ENHJ, Kamphorst W, Hol EM, Van Leeuwen FW (2003) Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. FASEB J 17:2014–2024. doi:10.1096/fj.03-0205com View ArticlePubMedGoogle Scholar
- Fischer DF, Van Dijk R, van Tijn P, Hobo B, Verhage MC, van der Schors RC, Li KW, van Minnen J, Hol EM, Van Leeuwen FW (2009) Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin. Neurobiol Aging 30:847–863. doi:10.1016/j.neurobiolaging.2008.06.009 View ArticlePubMedGoogle Scholar
- Hasegawa M, Arai T, Akiyama H, Nonaka T, Mori H, Hashimoto T, Yamazaki M, Oyanagi K (2007) TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 130:1386–1394. doi:10.1093/brain/awm065 View ArticlePubMedGoogle Scholar
- Hirano A, Kurland LT, Krooth RS, Lessell S (1961) Parkinsonism-dementia complex, an endemic disease on the island of Guam. I Clinical features Brain 84:642–661. doi:10.1093/brain/84.4.642 PubMedGoogle Scholar
- Hirano A, Malamud N, Kurland LT (1961) Parkinsonism-dementia complex, an endemic disease on the island of Guam. II Pathological features Brain 84:662–679. doi:10.1093/brain/84.4.662 PubMedGoogle Scholar
- Irmler M, Gentier RJG, Dennissen FJA, Schulz H, Bolle I, Hölter SM, Kallnik M, Cheng JJ, Klingenspor M, Rozman J, Ehrhardt N, Hermes DJHP, Gailus-Durner V, Fuchs H, Hrabě de Angelis M, Meyer HE, Hopkins DA, Van Leeuwen FW, Beckers J (2012) Long-term proteasomal inhibition in transgenic mice by UBB+1 expression results in dysfunction of central respiration control reminiscent of brainstem neuropathology in Alzheimer patients. Acta Neuropathol 124:187–197. doi:10.1007/s00401-012-1003-7 View ArticlePubMedPubMed CentralGoogle Scholar
- Lowe J, McDermott H, Landon M, Mayer RJ, Wilkinson KD (1990) Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol 161:153–160. doi:10.1002/path.1711610210 View ArticlePubMedGoogle Scholar
- Steele JC (2005) Parkinsonism-dementia complex of Guam. Mov Disord 20(Suppl 12):S99–S107. doi:10.1002/mds.20547 View ArticlePubMedGoogle Scholar
- Tan Z, Sun X, Hou F-S, Oh H-W, Hilgenberg LGW, Hol EM, van Leeuwen FW, Smith MA, O'Dowd DK, Schreiber SS (2007) Mutant ubiquitin found in Alzheimer's disease causes neuritic beading of mitochondria in association with neuronal degeneration. Cell Death Differ 14:1721–1732. doi:10.1038/sj.cdd.4402180 View ArticlePubMedPubMed CentralGoogle Scholar
- van Leeuwen FW, de Kleijn DPV, van den Hurk HH, Neubauer A, Sonnemans MAF, Sluijs JA, Köycü S, Ramdjielal RDJ, Salehi A, Martens GJM, Grosveld FG, Burbach JPH, Hol EM (1998) Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science. 279;242–247. doi:10.1126/science.279.5348.242
- Zouambia M, Fischer DF, Hobo B, De Vos RAI, Hol EM, Varndell IM, Sheppard PW, Van Leeuwen FW (2008) Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: consequences for proteomic analyses. Proteomics 8:1221–1236. doi:10.1002/pmic.200700679 View ArticlePubMedGoogle Scholar